Despite SARS-CoV-2 infection being associated with a suppressed production of endogenous EPO [15] and resistance, the administration of human recombinant EPO to COVID-19 patients with anemia requires a careful assessment of the benefits of maintaining adequate hemoglobin levels against the risks of thrombotic events, particularly in the pro-inflammatory and pro-thrombotic state induced by COVID-19. The gene discussed is EPO; the disease is COVID-19.